摘要
目的 探讨美罗培南与头孢哌酮钠治疗急性白血病合并重症肺部感染的临床效果。方法 98例急性白血病合并重症肺部感染患者,随机分为头孢哌酮钠组与美罗培南组,各49例。美罗培南组采用美罗培南治疗,头孢哌酮钠组采用头孢哌酮钠治疗。比较两组患者临床疗效,治疗期间药物不良反应发生率以及细菌培养阳性率、细菌清除率,治疗前后炎性因子变化情况。结果 美罗培南组治疗总有效率95.92%高于头孢哌酮钠组的83.67%,差异有统计学意义(P<0.05)。美罗培南组不良反应发生率8.16%明显低于头孢哌酮钠组的24.49%,差异有统计学意义(P<0.05)。美罗培南组细菌清除率91.30%高于头孢哌酮钠组的63.64%,差异有统计学意义(P<0.05)。治疗后,两组C反应蛋白、白细胞介素-6、肿瘤坏死因子-α、脑钠肽水平均优于本组治疗前,且美罗培南组C反应蛋白(7.56±0.37)mg/L、白细胞介素-6(41.56±3.05)pg/ml、肿瘤坏死因子-α(110.21±7.53)pg/ml、脑钠肽(425.16±10.58)pg/ml均优于头孢哌酮钠组的(16.15±1.42)mg/L、(53.28±2.76)pg/ml、(154.36±3.17)pg/ml、(879.66±17.21)pg/ml,差异均有统计学意义(P<0.05)。结论 美罗培南在急性白血病合并重症肺部感染患者治疗中效果更显著,可有效减少药物不良反应,改善肺部感染症状,安全性高,对改善患者生活质量有重要意义。
Objective To discuss the clinical effect of meropenem and cefoperazone sodium on acute leukemia with severe pulmonary infection.Methods A total of 98 patients with acute leukemia and severe pulmonary infection were randomly divided into cefoperazone sodium group and meropenem group,with 49 cases in each group.The meropenem group was treated with meropenem,and the cefoperazone sodium group was treated with cefoperazone sodium.Both groups were compared in terms of clinical efficacy,incidence of adverse drug reactions during treatment,positive rate of bacterial culture,bacterial clearance rate,and the changes of inflammatory factors before and after treatment.Results The total effective rate of treatment in the meropenem group was 95.92%,which was higher than 83.67%in the cefoperazone sodium group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the meropenem group was 8.16%,which was significantly lower than 24.49%in the cefoperazone sodium group,and the difference was statistically significant(P<0.05).The bacterial clearance rate was 91.30%in the meropenem group,which was higher than 63.64%in the cefoperazone sodium group,and the difference was statistically significant(P<0.05).After treatment,the levels of C-reactive protein,interleukin-6,tumor necrosis factor-αand brain natriuretic peptide in both groups were better than those before treatment in this group;the meropenem group had C-reactive protein of(7.56±0.37)mg/L,interleukin-6 of(41.56±3.05)pg/ml,tumor necrosis factor-αof(110.21±7.53)pg/ml,and brain natriuretic peptide of(425.16±10.58)pg/ml,which were better than(16.15±1.42)mg/L,(53.28±2.76)pg/ml,(154.36±3.17)pg/ml,and(879.66±17.21)pg/ml in the cefoperazone sodium group;all differences were statistically significant(P<0.05).Conclusion Melopenean has a more significant effect in patients with acute leukemia and severe pulmonary infection,and can effectively reduce adverse drug reactions,improve pulmonary infection symptoms.It has high safety and is of gr
作者
周立东
ZHOU Li-dong(Outpatient Western Medicine Bureau,Dalian Fifth People's Hospital,Dalian 116021,China)
出处
《中国实用医药》
2023年第6期6-9,共4页
China Practical Medicine
关键词
急性白血病
肺部感染
美罗培南
头孢哌酮钠
不良反应
临床效果
Acute leukemia
Pulmonary infection
Meropenem
Cefoperazone sodium
Adverse reactions
Clinical effect
